Bearish Options Bias in Mylan (MYL) Ahead on Earnings Next Week -Susquehanna

Mylan (MYL) Announces Launch of Avonza in India

Mylan Pharmaceuticals Private Limited, a subsidiary of Mylan N.V. (NASDAQ: MYL) has received marketing authorization from the Drug Controller General of India (DCGI) for its antiretroviral (ARV) drug Avonza (TLE400). Avonza is a fixed-dose combination comprised of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg, recommended by the World Health Organization (WHO) as an alternative first-line regimen for people being treated for... More

Mylan (MYL): Tactical Downside Trade

RBC Capital analyst, Randall Stanicky, reiterated his Sector Perform rating on shares of Mylan (NASDAQ: MYL) and cut his price target to $33 from $41 as negative data points continue to build. TEVA's 2Q update yesterday accentuated the risk the analyst sees into MYL's 2Q report and 2017... More

Teva Pharma (TEVA) PT Lowered to $27 at Cantor Fitzgerald

Cantor Fitzgerald lowered its price target on Teva Pharma (NYSE: TEVA) to $27.00 (from $31.00) while maintaining a Neutral rating following Q2 miss and weak guidance.

Analyst Louise Chen commented, "The decrease in our PT is driven by downwards earnings revisions and multiple contraction. This is appropriate, in... More

Mylan (MYL) Sinks Following Teva Results, Outlook

Mylan (NASDAQ: MYL) trades down 3.9% following weak results and outlook from rival Teva. Teva is down 15%.

Mylan (MYL) Taps Low Heading into Market Close

Mylan (NASDAQ: MYL) Taps Low Heading into Market Close

Generic Drug Environment May Be Getting Worse - Wells Fargo's Maris (MYL) (TEVA)

Wells Fargo's David Maris said Based on recent IMS data, and recent cautionary commentary they believe that the US generic drug environment may be worsening and that Mylan (NYSE: MYL) and Teva (NASDAQ: TEVA) may be... More